MONTREAL, Dec. 05, 2018 (GLOBE NEWSWIRE) --
Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and
Frankfurt: “6BX”) (the “Company”
or “Relevium”) is pleased to
announce it has retained Rohan Mendonza and his company, NForce
Labs Inc., to lead its Amazon business.
Rohan Mendonza, formerly Director of Operations
at Amazon.com Inc., is the CEO of NForce Labs, Inc., an e-commerce
consulting firm helping brands streamline supply chains, grow
organic marketing, and optimize paid advertising services with the
goal of maximizing clients’ return on investment. Prior to starting
NForce Labs, Rohan spent nine years with Amazon’s operations team.
Rohan graduated with an undergraduate degree in Mechanical
Engineering and worked for companies including GE Healthcare, and
Terumo Medical and has an MBA from the University of Michigan, Ross
School of Business.
The Amazon Marketplace represents a strategic
and important revenue stream for the company and the addition of
NForce to the team is expected to translate into organic growth,
improved new product adoption, optimized marketing spending and a
diversified and cost-efficient supply chain that is focused on
quality ingredients and innovation.
“We are very excited to have Mr. Mendonza
and the NForce Labs team lead our Amazon marketplace operations and
introduce world-class best practices to our portfolio of trusted
online brands. Mr Mendonza is an experienced executive and
brilliant strategist with an extensive international network in the
nutraceutical business, which will have a significant impact on our
OTC business. We are happy to welcome him and his team to
Relevium” stated Aurelio Useche, CEO.
About Relevium Technologies
Relevium is a publicly-traded company that
operates in the health and wellness industry, including legal
cannabis, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operations of brands and businesses in
the Health and Wellness markets and medical cannabis. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products. Relevium operates through
two wholly-owned subsidiaries:
BGX E-Health LLC (BGX): Based
in Orlando, Florida, BGX markets dietary supplements,
nutraceuticals, sports nutrition and cosmeceuticals primarily
through its Bioganix® brand portfolio in the US and Europe.
Relevium’s brands such as Bioganix® are sold at some of
the world’s largest retailers including such as Walmart.com and
Amazon.com.
The Company’s strategy for growing its brands
includes expanding its product offering, adding new distribution
channels and developing partnerships that add value through
exclusive ingredients. BGX is currently testing a complete line of
dietary supplements derived from Cannabis with an initial focus on
hemp derived, whole plant organic extract rich in CBD
(cannabidiol). The product line will be marketed through its brand
LeefyLyfe® and will be sold first in Europe and then North America.
The Company uses cannabinoids and ingredients that have achieved
GRAS status (generally accepted as safe) to create brands that are
sold via wholesale channels, retail channels and online
distribution.
Biocannabix Health Corporation
(BCX): Based in Montreal, Quebec, BCX is an
entrepreneurial venture to establish a vertically integrated
medical cannabis company in the Nutraceutical space. Located in the
city of Saint Laurent, the Company is in the process of licensing
and retrofitting a facility that will host a genetically focused
cannabis growth, extraction, formulation, research and development
and encapsulation of proprietary Nutraceutical and Medical
products.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking Statements
This release includes certain statements and information that may
constitute forward-looking information within the meaning of
applicable Canadian securities laws. All statements in this news
release, other than statements of historical facts, including
statements regarding future estimates, plans, objectives,
assumptions or expectations of future performance, including the
timing and completion of the proposed acquisitions, are
forward-looking statements and contain forward-looking information.
Generally, forward- looking statements and information can be
identified by the use of forward-looking terminology such as
"intends" or "anticipates", or variations of such words and phrases
or statements that certain actions, events or results "may",
"could", "should", "would" or "occur". Forward-looking statements
are based on certain material assumptions and analysis made by the
Company and the opinions and estimates of management as of the date
of this press release, including the assumptions that the Company
will be able to apply for and ultimately obtain an ACMPR licence,
the proposed business of Biocannabix will develop as anticipated,
that the Company will raise sufficient funds to develop the
Biocannabix business, and that the Company will obtain all
requisite regulatory approvals. These forward-looking statements
are subject to known and unknown risks, uncertainties and other
factors that may cause the actual results, level of activity,
performance or achievements of the Company to be materially
different from those expressed or implied by such forward-looking
statements or forward-looking information. Important factors that
may cause actual results to vary, include, without limitation, the
risk that the proposed business developments may not occur as
planned; the timing and receipt of requisite approvals and failure
to raise sufficient funds.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek safe
harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Relevium Technologies (CE) (USOTC:RLLVF)
Historical Stock Chart
From Nov 2024 to Dec 2024
Relevium Technologies (CE) (USOTC:RLLVF)
Historical Stock Chart
From Dec 2023 to Dec 2024
